FDA Approval Alert: The Need-to-Know | Ponatinib/Chemotherapy in Ph+ Acute Lymphoblastic Leukemia

In March 2024, The FDA granted accelerated approval to ponatinib in combination with chemotherapy as a treatment for adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
FDA Grants Accelerated Approval to Ponatinib Combo in Ph+ ALL
Article
Mar 19, 2024 3:56 PM
Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.